Deschloroclotizolam
![]()  | |
| Legal status | |
|---|---|
| Legal status | 
  | 
| Identifiers | |
IUPAC name 
  | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H11ClN4S | 
| Molar mass | 314.79 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
Deschloroclotizolam is a thienotriazolodiazepine derivative which has been sold as a designer drug, first being identified in Sweden in 2021.[1]
See also
References
- ↑ European Monitoring Centre for Drugs Drug Addiction (June 2022). New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System (PDF). European Monitoring Centre for Drugs and Drug Addiction. doi:10.2810/882318. ISBN 978-92-9497-737-3.
 
| Alcohols | 
  | 
|---|---|
| Barbiturates | 
  | 
| Benzodiazepines | 
  | 
| Carbamates | |
| Flavonoids | 
  | 
| Imidazoles | |
| Kava constituents | 
  | 
| Monoureides | 
  | 
| Neuroactive steroids | 
  | 
| Nonbenzodiazepines | |
| Phenols | |
| Piperidinediones | |
| Pyrazolopyridines | |
| Quinazolinones | |
| Volatiles/gases | 
  | 
| Others/unsorted | 
 
  | 
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators  | |
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
